The lipid-lowering activity of a series of novel
N-(benzoylphenyl)-5-fluoro-1
H-indole-2-carboxamide derivatives has been studied
in Triton WR-1339-induced hyperlipidemia in rats. The test animals were divided into four groups: control, hyperlipidemic, compound + 4% DMSO [C1:
N-(2-benzoylphenyl)-5-fluoro-1
H-indole-2-carboxamide (
1
[...] Read more.
The lipid-lowering activity of a series of novel
N-(benzoylphenyl)-5-fluoro-1
H-indole-2-carboxamide derivatives has been studied
in Triton WR-1339-induced hyperlipidemia in rats. The test animals were divided into four groups: control, hyperlipidemic, compound + 4% DMSO [C1:
N-(2-benzoylphenyl)-5-fluoro-1
H-indole-2-carboxamide (
1), C2:
N-(3-benzoylphenyl)-5-fluoro-1
H-indole-2-carboxamide (
2), C3:
N-(4-benzoylphenyl)-5-fluoro-1
H-indole-2-carboxamide (
3)]-treated
and bezafibrate (BF)-treated. At a dose of 15 mg/Kg body weight, compounds
2, 3 and BF significantly reduced elevated plasma triglycerodes levels after 12 h. Moreover, high density lipoprotein-cholesterol levels were significantly increased in all treated groups after 12 h compared to the hyperlipidemic control group, except for
C1 which was inactive. In sum, it may be stated that the results of the present
study demonstrated new properties of
some
N-(benzoylphenyl)-5-fluoro-
1H-indole-2-carboxamide derivatives as potent
lipid lowering agents and these beneficial activities
may contribute to their cardioprotective and antiatherosclerotic
role.
Full article
